Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

Biotechnology

Healthcare
$0.90 +3.01%

+$0.06 today

Market cap
$54.28M
Beta
1.19
P/E (TTM)
-4.2
EPS (TTM)
-$0.45
52W Low $1.07High $6.18

Volume 1.45M

Average 2.13M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$33.35M

FY 2025 · Annual

Investing Cash Flow

$47.74M

FY 2025 · Annual

Financing Cash Flow

$1.12M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(57.78M)(62.02M)(37.54M)(55.85M)(33.85M)
Depreciation & Amortization264.18K258.71K262.78K249.62K251.99K
Deferred Income Tax00000
Stock-Based Compensation7.11M8.29M5.75M7.97M6.09M
Change in Working Capital7.44M(3.44M)861.18K5.91M(5.18M)
Accounts Receivables00000
Inventory00000
Accounts Payables638.06K(886.08K)1.2M(1.16M)(21.99K)
Other Working Capital6.8M(2.56M)(343.25K)7.07M(5.16M)
Other Non-Cash Items409.47K283.91K339.65K(1.49M)(664.43K)
Operating Cash Flow(42.56M)(56.64M)(30.33M)(43.21M)(33.35M)
Capital Expenditures(7.81K)(16.32K)000
Acquisitions (Net)016.32K000
Purchases of Investments0(92.94M)0(96.92M)(40.26M)
Sales of Investments063M30M52M88M
Other Investing Activities0(16.32K)000
Investing Cash Flow(7.81K)(29.95M)30M(44.92M)47.74M
Debt Repayment00(1.04M)(292.5K)0
Common Stock Issued189.81M1.22M305.23K121.08K1.12M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities4.68M0(532.95K)0(444)
Financing Cash Flow194.5M1.22M(1.27M)(171.42K)1.12M
Effect of Forex Changes00000
Net Change in Cash151.93M(85.37M)(1.6M)(88.3M)15.51M
Free Cash Flow(42.56M)(56.65M)(30.33M)(43.21M)(33.35M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$33.8M
+ D&A$252.0K
+ Stock-Based Comp$6.1M
+ Deferred Tax$0
- Working Capital-$5.2M
- Other Non-Cash-$664.4K
= Operating Cash Flow-$33.3M
- Capex$0
= Free Cash Flow-$33.3M

Analysis

FY2025 free cash flow is -$33.3M. FCF conversion is 98.5% of net income. Operating cash flow was -$33.3M, with capex of $0. The largest bridge item is Stock-Based Comp at $6.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingAug 12, 2026
10-QQuarterly reportAug 6, 2026
8-KCurrent reportJul 30, 2026
SC 13G/ASC 13G/A filingJul 27, 2026
8-KCurrent reportJul 15, 2026

Does ALDX generate free cash flow?

Aldeyra Therapeutics, Inc. (ALDX) generated -$33.35M of free cash flow in fiscal 2025.

How much operating cash flow does ALDX produce?

Operating cash flow was -$33.35M, before capital expenditures of $0.00.